Document and Entity Information - USD ($) |
8 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 18, 2026 |
Jun. 30, 2025 |
|
| Cover [Abstract] | |||
| Document Type | 10-KT | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Trading Symbol | KALV | ||
| Entity Registrant Name | KalVista Pharmaceuticals, Inc. | ||
| Entity Central Index Key | 0001348911 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Shell Company | false | ||
| Document Annual Report | false | ||
| Title of 12(b) Security | Common Stock, $0.001 par value per share | ||
| Security Exchange Name | NASDAQ | ||
| Document Transition Report | true | ||
| Document Period Start Date | May 01, 2025 | ||
| Entity File Number | 001-36830 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 20-0915291 | ||
| Entity Address, Address Line One | 200 Crossing Boulevard | ||
| Entity Address, City or Town | Framingham | ||
| Entity Address, State or Province | MA | ||
| Entity Address, Postal Zip Code | 01702 | ||
| City Area Code | 857 | ||
| Local Phone Number | 999-0075 | ||
| Entity Common Stock, Shares Outstanding | 51,222,487 | ||
| Entity Public Float | $ 498,815,772 | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Documents Incorporated by Reference | Information required in response to Part III of Form 10-KT is hereby incorporated by reference to portions of the registrant’s Proxy Statement for the Annual Meeting of Stockholders to be held in 2026. The Proxy Statement will be filed by the registrant with the Securities and Exchange Commission no later than 120 days after the end of the registrant’s fiscal year ended December 31, 2025. |
||
| Auditor Opinion [Text Block] | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of KalVista Pharmaceuticals, Inc. and subsidiaries (the “Company”) as of December 31, 2025 and April 30, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in stockholders' (deficit) equity, and cash flows, for the eight month transition period ended December 31, 2025 and for each of the two years in the period ended April 30, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and April 30, 2025 and 2024, and the results of its operations and its cash flows for the eight month transition period ended December 31, 2025 and for each of the two years in the period ended April 30, 2025, in conformity with accounting principles generally accepted in the United States of America. |
||
| Auditor Firm ID | 34 | ||
| Auditor Name | Deloitte & Touche LLP | ||
| Auditor Location | Boston, Massachusetts |